Literature DB >> 27876525

IL-6 roles - Molecular pathway and clinical implication in pancreatic cancer - A systemic review.

Vlad-Vasile Pop1, Andrada Seicean2, Iulia Lupan3, Gabriel Samasca4, Claudia-Cristina Burz5.   

Abstract

Pancreatic cancer has attracted a great deal of attention owing to the poor outcome, increasing prevalence in the last years and delay diagnosis. Known as a complex disease, it involves genetic mutations, changes in tumour microenvironment and inflammatory component dominated by interleukin-6 and its activated pathways, like Janus Kinase-Signal Transducer and Activator of Translation3, Mitogen Activated Protein Kinase and Androgen receptor. The pro-inflammatory cytokine, plays a central role in oncogenesis, cancer progression, invasiveness, microenvironment changes, treatment resistance, prognosis and associated co morbidities like cachexia and depression. Fulfilling these roles IL-6 requires special attention to understand its complexity in PC development.
Copyright © 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Interleukin-6; Oncogenesis; Pancreatic cancer; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27876525     DOI: 10.1016/j.imlet.2016.11.010

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  27 in total

Review 1.  Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models.

Authors:  Sally E Henderson; Neil Makhijani; Thomas A Mace
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

2.  Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells.

Authors:  Florent Colomb; Weikun Wang; Deborah Simpson; Mudaser Zafar; Robert Beynon; Jonathan M Rhodes; Lu-Gang Yu
Journal:  J Biol Chem       Date:  2017-03-31       Impact factor: 5.157

3.  Preoperative sarcopenia status is associated with lymphovascular invasion in upper tract urothelial carcinoma patients treated with radical nephroureterectomy.

Authors:  Tadatsugu Anno; Eiji Kikuchi; Keishiro Fukumoto; Koichiro Ogihara; Mototsugu Oya
Journal:  Can Urol Assoc J       Date:  2017-12-22       Impact factor: 1.862

4.  Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.

Authors:  Yanqin Wu; Wenzhe Fan; Miao Xue; Bihui Zhong; Shenghong Zhang; Yu Wang; Wang Yao; Yue Zhao; Jiaping Li
Journal:  Oncologist       Date:  2019-06-27

5.  Methylation of immune-regulatory cytokine genes and pancreatic cancer outcomes.

Authors:  Brian Z Huang; Alexandra M Binder; Catherine A Sugar; Chun R Chao; Veronica Wendy Setiawan; Zuo-Feng Zhang
Journal:  Epigenomics       Date:  2020-09-01       Impact factor: 4.778

Review 6.  Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review.

Authors:  William Paul Skelton; Hiral Parekh; Jason S Starr; Jose Trevino; Jessica Cioffi; Steven Hughes; Thomas J George
Journal:  J Gastrointest Cancer       Date:  2018-03

7.  Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.

Authors:  Xiang Chen; Jilai Tian; Gloria H Su; Jiayuh Lin
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

8.  Interleukin-6 as a biomarker in patients with hepatobiliary cancers.

Authors:  Rohit Gosain; Sidra Anwar; Austin Miller; Renuka Iyer; Sarbajit Mukherjee
Journal:  J Gastrointest Oncol       Date:  2019-06

9.  Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma.

Authors:  Asmita Chopra; Ruben Zamora; Yoram Vodovotz; Jacob C Hodges; Derek Barclay; Randall Brand; Richard L Simmons; Kenneth K Lee; Alessandro Paniccia; Pranav Murthy; Michael T Lotze; Brian A Boone; Amer H Zureikat
Journal:  J Immunother       Date:  2021-06-01       Impact factor: 4.912

Review 10.  The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Authors:  Shahin Shams; Joseph M Martinez; John R D Dawson; Juan Flores; Marina Gabriel; Gustavo Garcia; Amanda Guevara; Kaitlin Murray; Noah Pacifici; Maxemiliano V Vargas; Taylor Voelker; Johannes W Hell; Judith F Ashouri
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.